Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-α in TP53-Mutant AML/MDS Post-HSCT
NCT07449286Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon alfa in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Peking University People's Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
interferon alfa
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07449286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449286.